Clinical Significance of Peripheral Blood Mammary Gland Globin Testing in Breast Cancer Patients_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LIWen-fang , WANGMing-hua , WANGGeng ,  ZAOZong-bing

Third Department of General Surgery, Afficiated Taihe Hospital, Hubei Medical College, Shiyan 442000, Hubei Province, China;

Corresponding author：

ZAOZong-bing, Email: zzb54@163.com

Keywords：

Breast cancer; Human mammary gland globin; mRNA

DOI：

10.7507/1007-9424.20150022

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To test the expressions of human mammary gland globin (hMAM) mRNA in the peripheral blood of breast cancer and breast benign lesions patients, try to provide the theory basis for the choice of breast cancer molecular marker. Methods Polymerase chain reaction (PCR) technology was used to detect the expressions of hMAM mRNA in peripheral blood of 78 cases of breast cancer patients, 15 cases of hyperplasia of mammary gland, and 15 cases of breast fibroadenoma. The relationship between the expressions of hMAM-mRNA in peripheral blood of breast cancer patients with patient's age, tumor size, pathological type, tumor stage, axillary lymph node metastasis, and the ER, PR and HER-2 status were analyzed. Results The expressions of hMAM-mRNA in peripheral blood were not detected in breast hyperplasia and breast fibroadenoma patients, but the peripheral blood hMAM-mRNA expression rate in breast cancer patients was 48.72% (38/78), the difference was statistically significant (χ²=12.357, P=0.000). The expression of peripheral blood hMAM mRNA was not related to the patient's age, tumor size, pathological type, and ER, PR and HER-2 status (P > 0.05), but the expression of peripheral blood hMAM mRNA was related to the clinical staging of tumor (Z=-2.214, P=0.027) and lymph node metastasis status (Z=-2.754, P=0.006). Conclusion Peripheral blood hMAM-mRNA detected is a sign of breast cancer, further research is needed to confirm whether hMAM mRNA detection in peripheral blood correlates with poor prognosis of breast cancer patients.

Citation： LIWen-fang, WANGMing-hua, WANGGeng, ZAOZong-bing. Clinical Significance of Peripheral Blood Mammary Gland Globin Testing in Breast Cancer Patients. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(1): 91-94. doi: 10.7507/1007-9424.20150022 Copy

1.	李赛男, 耿翠芝.乳腺癌分子分型与腋窝淋巴结外科处理.中国普外基础与临床杂志, 2014, 21(5):589-592.
2.	Illyes I, Tokes AM, Kovacs A, et al.In breast cancer patients sentinel lymph node metastasis characteristics predict further axillary involvement.Virchows Arch, 2014, 465(1):15-24.
3.	Gujam FJ, Going JJ, Mohammed ZM, et al.Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer.BMC Cancer, 2014, 14:676.
4.	Tjensvoll K, Oltedal S, Farmen RK, et al.Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict outcome in operable breast cancer patients.Clin Breast Cancer, 2010, 10(5):378-384.
5.	Dono M, Ferro P, Benedetti L, et al.Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis.J Neurooncol, 2009, 91(3):295-298.
6.	吴国球, 张臣, 孙宏伟, 等.建立人乳腺珠蛋白mRNA FQ-PCR方法用于乳腺癌微小转移的诊断.临床检验杂志, 2006, 24(2):85-88.
7.	Osako T, Iwase T, Ushijima M, et al.Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ.Cancer Sci, 2014, 105(5):576-582.
8.	Osako T, Iwase T, Kimura K, et al.Detection of occult invasion in ductal carcinoma in situ of the breast with sentinel node metastasis.Cancer Sci, 2013, 104(4):453-457.
9.	吴炅, 杨犇龙.2012年乳腺癌研究进展回顾.中华乳腺病杂志:电子版, 2013, 7(1):4-6.
10.	Lee GW, Kim JY, Koh EH, et al.Plasma human mammaglobin mRNA associated with poor outcome in patients with breast cancer.Genet Mol Res, 2012, 11(4):4034-4042.
11.	Zhao S, Yang H, Zhang M, et al.Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.Cell Biochem Biophys, 2013, 65(2):263-273.
12.	Strati A, Markou A, Parisi C, et al.Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR.BMC Cancer, 2011, 11:422.
13.	Yuan ZY, Dai T, Wang SS, et al.Overexpression of ETV4 protein in triple-negative breast cancer is associated with a higher risk of distant metastasis.Oncol Targets Ther, 2014, 7:1733-1742.
14.	Chen HW, Du CW, Wei XL, et al.Cytoplasmic CXCR4 high expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer.Curr Mol Med, 2013, 13(3):410-416.
15.	Ferro P, Franceschini MC, Bacigalupo B, et al.Detection of circulating tumour cells in breast cancer patients using human mammaglobin RT-PCR:association with clinical prognostic factors.Anticancer Res, 2010, 30(6):2377-2382.
16.	Liu Y, Ma L, Liu X, et al.Expression of human mammaglobin as a marker of bone marrow micrometastasis in breast cancer.Exp Ther Med, 2012, 3(3):550-554.
17.	Dai X, Chen A, Bai Z.Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling.Sci Rep, 2014, 4:6566.
18.	Pivot X, Gligorov J, Müller V, et al.Patients'preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer:final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.Ann Oncol, 2014, 25(10):1979-1987.
19.	Orlando L, Giotta F, Lorusso V, et al.Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer:results of a PhaseⅡGOIM study.Future Oncol, 2014, 10(5):725-733.
20.	Attard C, Pepper A, Brown S, et al.Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.J Med Econ, 2014, 27:1-38.
21.	Vici P, Pizzuti L, Natoli C, et al.Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras:a real-world multicenter observational analysis.Breast Cancer Res Treat, 2014, 147(3):599-607.
22.	Esfahani K, Ferrario C, Le P, et al.The trastuzumab and vinorelbine combination:an alternative to taxane-based chemotherapy for early-stage and locally advanced her2-positive breast cancer.Curr Oncol, 2014, 21(5):e723-e727.
23.	Rouanet P, Roger P, Rousseau E, et al.HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer:results from a French regional cohort.Cancer Med, 2014, 3(1):134-142.
24.	Nassar A, Khoor A, Radhakrishnan R, et al.Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy:a 5-year experience with invasive ductal and lobular carcinomas.Int J Clin Exp Pathol, 2014, 7(9):6254-6261.
25.	Koh EH, Cho YW, Mun YJ, et al.Upregulation of human mammaglobin reduces migration and invasion of breast cancer cells.Cancer Invest, 2014, 32(1):22-29.

1. 李赛男, 耿翠芝.乳腺癌分子分型与腋窝淋巴结外科处理.中国普外基础与临床杂志, 2014, 21(5):589-592.
2. Illyes I, Tokes AM, Kovacs A, et al.In breast cancer patients sentinel lymph node metastasis characteristics predict further axillary involvement.Virchows Arch, 2014, 465(1):15-24.
3. Gujam FJ, Going JJ, Mohammed ZM, et al.Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer.BMC Cancer, 2014, 14:676.
4. Tjensvoll K, Oltedal S, Farmen RK, et al.Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict outcome in operable breast cancer patients.Clin Breast Cancer, 2010, 10(5):378-384.
5. Dono M, Ferro P, Benedetti L, et al.Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis.J Neurooncol, 2009, 91(3):295-298.
6. 吴国球, 张臣, 孙宏伟, 等.建立人乳腺珠蛋白mRNA FQ-PCR方法用于乳腺癌微小转移的诊断.临床检验杂志, 2006, 24(2):85-88.
7. Osako T, Iwase T, Ushijima M, et al.Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ.Cancer Sci, 2014, 105(5):576-582.
8. Osako T, Iwase T, Kimura K, et al.Detection of occult invasion in ductal carcinoma in situ of the breast with sentinel node metastasis.Cancer Sci, 2013, 104(4):453-457.
9. 吴炅, 杨犇龙.2012年乳腺癌研究进展回顾.中华乳腺病杂志:电子版, 2013, 7(1):4-6.
10. Lee GW, Kim JY, Koh EH, et al.Plasma human mammaglobin mRNA associated with poor outcome in patients with breast cancer.Genet Mol Res, 2012, 11(4):4034-4042.
11. Zhao S, Yang H, Zhang M, et al.Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.Cell Biochem Biophys, 2013, 65(2):263-273.
12. Strati A, Markou A, Parisi C, et al.Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR.BMC Cancer, 2011, 11:422.
13. Yuan ZY, Dai T, Wang SS, et al.Overexpression of ETV4 protein in triple-negative breast cancer is associated with a higher risk of distant metastasis.Oncol Targets Ther, 2014, 7:1733-1742.
14. Chen HW, Du CW, Wei XL, et al.Cytoplasmic CXCR4 high expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer.Curr Mol Med, 2013, 13(3):410-416.
15. Ferro P, Franceschini MC, Bacigalupo B, et al.Detection of circulating tumour cells in breast cancer patients using human mammaglobin RT-PCR:association with clinical prognostic factors.Anticancer Res, 2010, 30(6):2377-2382.
16. Liu Y, Ma L, Liu X, et al.Expression of human mammaglobin as a marker of bone marrow micrometastasis in breast cancer.Exp Ther Med, 2012, 3(3):550-554.
17. Dai X, Chen A, Bai Z.Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling.Sci Rep, 2014, 4:6566.
18. Pivot X, Gligorov J, Müller V, et al.Patients'preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer:final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.Ann Oncol, 2014, 25(10):1979-1987.
19. Orlando L, Giotta F, Lorusso V, et al.Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer:results of a PhaseⅡGOIM study.Future Oncol, 2014, 10(5):725-733.
20. Attard C, Pepper A, Brown S, et al.Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.J Med Econ, 2014, 27:1-38.
21. Vici P, Pizzuti L, Natoli C, et al.Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras:a real-world multicenter observational analysis.Breast Cancer Res Treat, 2014, 147(3):599-607.
22. Esfahani K, Ferrario C, Le P, et al.The trastuzumab and vinorelbine combination:an alternative to taxane-based chemotherapy for early-stage and locally advanced her2-positive breast cancer.Curr Oncol, 2014, 21(5):e723-e727.
23. Rouanet P, Roger P, Rousseau E, et al.HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer:results from a French regional cohort.Cancer Med, 2014, 3(1):134-142.
24. Nassar A, Khoor A, Radhakrishnan R, et al.Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy:a 5-year experience with invasive ductal and lobular carcinomas.Int J Clin Exp Pathol, 2014, 7(9):6254-6261.
25. Koh EH, Cho YW, Mun YJ, et al.Upregulation of human mammaglobin reduces migration and invasion of breast cancer cells.Cancer Invest, 2014, 32(1):22-29.

Previous Article
我所见的美国心脏外科医师培养
Next Article
肠系膜上静脉损伤8例教训分析

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Clinical Significance of Peripheral Blood Mammary Gland Globin Testing in Breast Cancer Patients

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content